Advisory Board Member Profile 2017
Partha Anbil
|
|
The ConfluenceElite Group, LLC
Principal 
Areas of Expertise
Big Data Strategy; Big Data & Marketing; Big Data & Operations; Data Analytics for Finance & HR; Reducing Risk Through Big Data; Driving Innovation with Big Data; Big Data Technologies & Infrastructure; Implementation Issues with Big Data
|
Partha Anbil recently re-joined IBM as Sr. Client Executive in Health & Life Sciences practice. Mr. Anbil has over two decades of management consulting experience in Health & Life Sciences industry. He held leadership roles as Executive Advisor, Booz & Company (now Strategy&), Associate Partner, Strategy & Transformation practice at IBM Global Business Services, Practice Leader, Wolters Kluwer Pharma Solutions (now Symphony), Senior Principal at IMSHealth Management Consulting and Director at KPMG consulting, & Senior Manager at PricewaterhouseCoopers (PwC) LLP. He has consulted & counseled Life Sciences clients in structuring solutions for strategic, operational & organizational challenges and issues.
Mr. Anbil has deep domain expertise in health care & life sciences industry and knowledge in various therapeutic areas and disease conditions such as Cardiovascular, CNS, Genitourinary, Immunology & Inflammation, Infectious Diseases, Metabolic, Oncology, and Respiratory, etc. He is knowledgeable in various data assets (IMSHealth, WK, SDI, VERISPAN & HMS) such as prescribing, claims, sales, census data --National Audit, Anonymized Patient Longitudinal Data (APLD), Pharmetrics, Managed Market (Plantrack, DCL), Fingertip formulary, Promotional audit, A.C. Nielson (PRIZM & CLARITAS), Symphony IRI, non-retail (DDD/HCOS) and other HEOR (MarketScan, i3) data assets. Also familiar with R&D related information assets such as such as IBM’s PC&I, SIIP, Thomson Reuters’ GeneGo, Web of Science, Coretellis, Integrity, Newport, IDRAC and KOLexperts and CMR R&D and Clinical Benchmark, R&D Factbook, and Elsevier’s Pharmapedium, Embase etc., as well as Clinical and R&D information assets such as Clinicaltrials.gov, ConvergenceCT, National Oncology Database (NODB), National Health and Nutrition Examination Survey (NHANES), Surveillance, Epidemiology and End Results (SEER). Familiar with deals databases such as Evaluate Pharma, Thomson Reuters Pharma, Partnering, & Forecast, Deloitte Recap, Strategic Transactions, and Medtrack, etc. He is also proficient in business analytics & optimization using both structured & unstructured data. He has the multidisciplinary educational background and cross-functional experience. Mr. Anbil received an MBA in Corporate Strategy and Business Development from the MIT Sloan School of Management, Cambridge, Massachusetts, and an M.S. in Corporate Finance and M.A. in Econometrics from the University of Toledo, Toledo, OH. He also has an M.I.B (Masters in International Business) from the Indian Institute of Foreign Trade (IIFT), and a B.S. in Electrical Engineering. He speaks at the various industry related conferences such as American Marketing Association (AMA), Pharmaceutical Marketing Sciences Association (PMSA), Pharmaceutical Marketing Research Group (PMRG), Synygy’s Sales Performance, PharmaIQ, and other conferences organized by CBI, EyeforPharma, Pharmaforce, Jacob Fleming, exlpharma and Marcus Evans, etc. In the thought leadership arena, he had published many articles in business journals and magazines such as PharmExec, PM360, MM&M, PharmaVoice, and Pharmaceutical Commerce, etc. and contributed internal white papers for the consulting firms he had worked. He is also on the editorial advisory boards of PM360 magazine – A premier trade publication for pharma marketers and Managed care magazine – A premier trade publication for managed care professionals.
|
